Developer docs
API playgroundTry for free, no card

Search company profiles

JRS Pharma

Full company profile

uuid0009xje

Namestring
JRS Pharma
Legal namestring
JRS PHARMA GmbH + Co. KG
Websiteurl
jrspharma.com
Company typeenum
Private
Founded yearint
1878
Descriptiontext

JRS Pharma, legally JRS PHARMA GmbH + Co. KG, is a privately held German manufacturer of pharmaceutical and nutraceutical excipients and ready-to-use tablet coatings, headquartered in Rosenberg and operating as a member of the family-owned JRS Group (founded 1878). The company sells a broad branded portfolio spanning microcrystalline cellulose and powdered cellulose grades (VIVAPUR, EMCOCEL, EMCOMPRESS, EMDEX, ARBOCEL), high-functionality co-processed composites (PROSOLV SMCC, RX, NX, 730, ODT G2), superdisintegrants (VIVASOL, VIVASTAR, EXPLOTAB, VIVAPHARM PVPP, EMCOSOY), binders (VIVAPHARM PVP, PVP/VA), lubricants (PRUV sodium stearyl fumarate, LUBRITAB), carriers (VIVAPUR MCC Spheres), thickeners/stabilizers (VIVAPHARM alginates, VIVAPUR MCG), and the VIVACOAT ready-to-use coating line including the 2026-launched TiO2-free VIVACOAT free. Underlying technology is built on cellulose and alginate chemistries plus co-processing techniques that combine MCC with colloidal silicon dioxide, superdisintegrants and lubricants to deliver differentiated compaction, flow and disintegration performance. Products are cGMP/IPEC GMP and ISO 9001 certified, meeting NF, JP and Ph. Eur. pharmacopoeia monographs.

JRS Pharma monetizes primarily through one-time unit sales of excipients and coatings priced ex-works EUR per kilogram, with publicly visible prices ranging from approximately €19.75/kg for HPMC coating polymer up to €48/kg for enteric VIVACOAT protect E. Distribution runs through direct enterprise sales to pharmaceutical and nutraceutical manufacturers globally, supplemented by an e-commerce platform (coatings-shop.com) for sample and small-volume orders in the coatings segment. Technical services function as a strategic overlay rather than a major revenue stream: Technical Competence Centers in Germany and the U.S. plus application labs in Mexico, Brazil, China and India provide formulation support, customer seminars and on-site troubleshooting, reinforcing product pull-through.

The customer base is split across pharmaceutical (solid and liquid dosage forms), nutraceutical (supplements and chewable tablets), animal health (veterinary suspensions, joint health tablets), and contract biopharma services delivered through wholly-owned subsidiaries Celonic (biotherapeutic CDMO with up to 1,000L GMP manufacturing) and ProJect Pharmaceutics (protein, peptide and ADC formulation). Manufacturing footprint spans three continents with dedicated sites for MCC (Weissenborn), CMS and croscarmellose (Pirna), fiber (Schoolcraft, MI), and alginates (Landerneau, France).

Short descriptiontext

JRS Pharma is a privately held German manufacturer of pharmaceutical and nutraceutical excipients and ready-to-use tablet coatings, serving global drug and supplement makers via cellulose- and alginate-based technologies and a three-continent production footprint.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRosenberg, Germany
HQ citystring
Rosenberg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical excipients, nutraceutical excipients, tablet coating systems, direct compression excipients, cellulose-based excipients
Industry1 code
1Compounding Ingredient & API Distributors (Pharma Supply)
CodeHLAIAJAOPrimaryYes
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Miscellaneous Chemical Products2890
Product category
Pharmaceutical Excipients
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical Excipients
TypeOne Time License
Description

JRS Pharma generates revenue through the sale of pharmaceutical excipients including microcrystalline cellulose, powdered cellulose, superdisintegrants, binders, lubricants, and alginates for solid and liquid dosage forms.

jrspharma.com
2Ready-to-Use Coatings
TypeOne Time License
Description

Sale of VIVACOAT® coating systems for pharmaceutical and nutraceutical tablets, including standard, high-adhesion, enteric, moisture barrier, and specialized coatings.

jrspharma.com
3Technical Services
TypeProfessional Services
Description

Formulation support, troubleshooting, customer seminars, and technical support through Technical Competence Centers worldwide.

jrspharma.com
4Biopharma Services
TypeManaged Services
Description

Through affiliated companies Celonic and ProJect Pharmaceutics - contract development and manufacturing of biotherapeutics, including production cell lines, GMP manufacturing, and formulation services.

jrspharma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
Pricing details4 tiers
1VIVACOAT® S Standard Pharma (20kg) at €29.50/kg
ModelUnit PricingBilling cadencePay-as-you-go
Notes

VIVACOAT® S - Standard, clear, Pharma grade, 20kg package, Ex Works Price €29.50/kg

jrspharma.com
2VIVACOAT® A High Adhesion Pharma (25kg) at €31.00-37.00/kg
ModelUnit PricingBilling cadencePay-as-you-go
Notes

VIVACOAT® A - high adhesion, Pharma grade, 25kg package, colors available (white €31.00, yellow/red/green/blue €33.50-37.00/kg)

jrspharma.com
3VIVAPHARM® HPMC E5 Pharma/Nutra at €19.75/kg
ModelUnit PricingBilling cadencePay-as-you-go
Notes

VIVAPHARM® HPMC E5, Hypromellose coating polymer, Pharma and Nutritional Supplements grade, Ex Works Price €19.75/kg

jrspharma.com
4VIVACOAT® protect E Enteric Pharma (20kg) at €48.00/kg
ModelUnit PricingBilling cadencePay-as-you-go
Notes

VIVACOAT® protect E - Acid-Protect/Enteric coating, Pharma grade, Ex Works Price €48.00/kg

jrspharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

JRS Pharma manufactures and supplies functional excipients and coating systems used by pharmaceutical and nutraceutical companies to formulate solid oral dosage forms such as tablets and capsules. Its portfolio covers binders, fillers, disintegrants, glidants, controlled-release matrix polymers, and ready-to-use film coating systems, complemented by technical services for formulation and coating process support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 100% satisfactory ratings from top pharmaceutical and nutraceutical companies
+1 more record
Product overview1 text field

JRS Pharma offers a comprehensive portfolio of pharmaceutical and nutraceutical excipients and coating solutions, organized into distinct product lines: (1) High Functionality Excipients including PROSOLV® SMCC (silicified MCC), PROSOLV® RX/NX (all-in-one composites), and PROSOLV® 730 (for lipophilic actives); (2) Core Excipients spanning microcrystalline cellulose variants (VIVAPUR®, EMCOCEL®), superdisintegrants (VIVASOL®, VIVASTAR®, EXPLOTAB®, VIVAPHARM® PVPP), binders (VIVAPHARM® PVP, EMDEX®), lubricants (PRUV®, LUBRITAB®), functional fillers (ARBOCEL®, EMCOMPRESS®, COMPACTROL®), thickeners (VIVAPHARM® Alginates, VIVAPUR® MCG), and specialized disintegrants (EMCOSOY®); (3) VIVACOAT® ready-to-use coating systems including TiO2-free formulations, moisture barriers, enteric coatings, and aesthetic coatings; (4) Technical Services with global Technical Competence Centers providing formulation support and troubleshooting. The portfolio serves pharmaceutical, nutraceutical, animal health, and contract manufacturing industries.

Product and service1 record
1VIVAPUR MCC Spheres
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Celonic is a contract manufacturing organization (CMO) offering development and manufacture of biotherapeutics. They provide development of high yield production cell lines, up-stream and down-stream processes, full GMP analytics, and manufacture of active pharmaceutical ingredients (API) in scales up to 1000L cell cultures. Celonic also performs stability studies of drug substances and products. They joined the JRS Pharma Family to meet growing demands for biotech services.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

ProJect Pharmaceutics transforms proteins, peptides, and ADCs/Cytotoxics into pioneering drugs. With expertise in design, optimization, and customization of pharmaceutical formulations, they deliver and transfer formulations from pilot lab to large-scale manufacturing under GMP environment. Joined the JRS Pharma Family to expand biopharma services.

3Landerneau Marine Technologies SAS
Strategic tierCoreTypeTechnology or Integration
Description

Alginate production facility located on the coast of Brittany, France. Brown algae grow on the continental shelf close to the production site enabling shortest transport routes. Harvesting is regulated by local authorities for optimal sustainability. By-products are re-used or recycled as fertilizer for local agricultural production.

jrspharma.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global chemical giant with a broad pharmaceutical excipients and active ingredient portfolio. Directly comparable to JRS Pharma in binders, disintegrants, and coatings, though BASF spans a far wider industrial chemicals footprint.

TypeDirect peer
Description

French-headquartered global leader in pharmaceutical excipients including microcrystalline cellulose, starches, and cyclodextrins. Closest direct competitor to JRS Pharma across both pharma and nutraceutical excipients.

3IFF (DuPont Nutrition & Biosciences)
TypeBroad incumbent
Description

Acquired DuPont's N&B division and offers a large portfolio of pharmaceutical excipients and coatings under the Health & Biosciences segment. Comparable in cellulose-based excipients and broader specialty ingredients.

TypeBroad incumbent
Description

German specialty chemicals company with a healthcare-focused excipients portfolio including silica, polyesters, and amino acid derivatives. Comparable in serving global pharma manufacturers with high-purity functional excipients.

TypeBroad incumbent
Description

Major Japanese specialty chemicals producer offering HPMC, PVP, and other pharmaceutical-grade excipients. Directly competitive with JRS Pharma's VIVAPHARM® HPMC and PVP product lines.

TypeDirect peer
Description

Netherlands-based dedicated pharmaceutical excipients supplier offering lactose, MCC, superdisintegrants, and inhalation-grade materials. Highly comparable in scale and focus to JRS Pharma's excipient core business.

TypeDirect peer
Description

Specialist in film coatings, modified release technologies, and excipients for the pharmaceutical and nutraceutical industries. Direct competitor to JRS Pharma's VIVACOAT® coating line and ready-to-use formulations.

TypeDirect peer
Description

US-based specialty chemicals company with a pharmaceutical division offering tablet coatings, disintegrants, and binders. Directly comparable in serving pharma and nutraceutical excipient needs.

TypeEmerging player
Description

Specialty ingredient supplier within Air Liquide offering pharmaceutical and nutraceutical excipients including polymers and coating systems. Comparable in functional coatings and excipient innovation.

TypeEmerging player
Description

Irish taste and nutrition company with a pharmaceutical excipients offering including binders, coatings, and taste-masking technologies. Increasingly comparable to JRS Pharma's nutraceutical-focused portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

JRS Pharma

Pharmaceutical Excipientsjrspharma.com

JRS Pharma is a privately held German manufacturer of pharmaceutical and nutraceutical excipients and ready-to-use tablet coatings, serving global drug and supplement makers via cellulose- and alginate-based technologies and a three-continent production footprint.

What JRS Pharma does

JRS Pharma, legally JRS PHARMA GmbH + Co. KG, is a privately held German manufacturer of pharmaceutical and nutraceutical excipients and ready-to-use tablet coatings, headquartered in Rosenberg and operating as a member of the family-owned JRS Group (founded 1878). The company sells a broad branded portfolio spanning microcrystalline cellulose and powdered cellulose grades (VIVAPUR, EMCOCEL, EMCOMPRESS, EMDEX, ARBOCEL), high-functionality co-processed composites (PROSOLV SMCC, RX, NX, 730, ODT G2), superdisintegrants (VIVASOL, VIVASTAR, EXPLOTAB, VIVAPHARM PVPP, EMCOSOY), binders (VIVAPHARM PVP, PVP/VA), lubricants (PRUV sodium stearyl fumarate, LUBRITAB), carriers (VIVAPUR MCC Spheres), thickeners/stabilizers (VIVAPHARM alginates, VIVAPUR MCG), and the VIVACOAT ready-to-use coating line including the 2026-launched TiO2-free VIVACOAT free. Underlying technology is built on cellulose and alginate chemistries plus co-processing techniques that combine MCC with colloidal silicon dioxide, superdisintegrants and lubricants to deliver differentiated compaction, flow and disintegration performance. Products are cGMP/IPEC GMP and ISO 9001 certified, meeting NF, JP and Ph. Eur. pharmacopoeia monographs.

JRS Pharma monetizes primarily through one-time unit sales of excipients and coatings priced ex-works EUR per kilogram, with publicly visible prices ranging from approximately €19.75/kg for HPMC coating polymer up to €48/kg for enteric VIVACOAT protect E. Distribution runs through direct enterprise sales to pharmaceutical and nutraceutical manufacturers globally, supplemented by an e-commerce platform (coatings-shop.com) for sample and small-volume orders in the coatings segment. Technical services function as a strategic overlay rather than a major revenue stream: Technical Competence Centers in Germany and the U.S. plus application labs in Mexico, Brazil, China and India provide formulation support, customer seminars and on-site troubleshooting, reinforcing product pull-through.

The customer base is split across pharmaceutical (solid and liquid dosage forms), nutraceutical (supplements and chewable tablets), animal health (veterinary suspensions, joint health tablets), and contract biopharma services delivered through wholly-owned subsidiaries Celonic (biotherapeutic CDMO with up to 1,000L GMP manufacturing) and ProJect Pharmaceutics (protein, peptide and ADC formulation). Manufacturing footprint spans three continents with dedicated sites for MCC (Weissenborn), CMS and croscarmellose (Pirna), fiber (Schoolcraft, MI), and alginates (Landerneau, France).

JRS Pharma firmographics

Firmographics
Name
JRS Pharma
Legal name
JRS PHARMA GmbH + Co. KG
Website
https://jrspharma.com
Company type
Private
Founded year
1878
Operating status
Operating
Headcount range
11–50 employees
Short description
JRS Pharma is a privately held German manufacturer of pharmaceutical and nutraceutical excipients and ready-to-use tablet coatings, serving global drug and supplement makers via cellulose- and alginate-based technologies and a three-continent production footprint.
Ownership category
akta.pro rank

JRS Pharma industry classification

Industry
Product category
Pharmaceutical Excipients
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Miscellaneous Chemical Products (2890)
akta.pro primary industry
Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

  • Pharmaceutical excipients
  • Nutraceutical excipients
  • Tablet coating systems
  • Direct compression excipients
  • Cellulose-based excipients

Where JRS Pharma is headquartered

Location

Headquarters

HQ city
Rosenberg
HQ country
Germany
HQ region
Europe

Offices7 records

Markets served

JRS Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. Pharmaceutical Excipients: JRS Pharma generates revenue through the sale of pharmaceutical excipients including microcrystalline cellulose, powdered cellulose, superdisintegrants, binders, lubricants, and alginates for solid and liquid dosage forms.
  2. Ready-to-Use Coatings: Sale of VIVACOAT® coating systems for pharmaceutical and nutraceutical tablets, including standard, high-adhesion, enteric, moisture barrier, and specialized coatings.
  3. Technical Services: Formulation support, troubleshooting, customer seminars, and technical support through Technical Competence Centers worldwide.
  4. Biopharma Services: Through affiliated companies Celonic and ProJect Pharmaceutics - contract development and manufacturing of biotherapeutics, including production cell lines, GMP manufacturing, and formulation services.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goVIVACOAT® S Standard Pharma (20kg) at €29.50/kg
Unit PricingPay-as-you-goVIVACOAT® A High Adhesion Pharma (25kg) at €31.00-37.00/kg
Unit PricingPay-as-you-goVIVAPHARM® HPMC E5 Pharma/Nutra at €19.75/kg
Unit PricingPay-as-you-goVIVACOAT® protect E Enteric Pharma (20kg) at €48.00/kg

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

JRS Pharma product offering

Product offering

Core offering

JRS Pharma manufactures and supplies functional excipients and coating systems used by pharmaceutical and nutraceutical companies to formulate solid oral dosage forms such as tablets and capsules. Its portfolio covers binders, fillers, disintegrants, glidants, controlled-release matrix polymers, and ready-to-use film coating systems, complemented by technical services for formulation and coating process support.

Product overview

JRS Pharma offers a comprehensive portfolio of pharmaceutical and nutraceutical excipients and coating solutions, organized into distinct product lines: (1) High Functionality Excipients including PROSOLV® SMCC (silicified MCC), PROSOLV® RX/NX (all-in-one composites), and PROSOLV® 730 (for lipophilic actives); (2) Core Excipients spanning microcrystalline cellulose variants (VIVAPUR®, EMCOCEL®), superdisintegrants (VIVASOL®, VIVASTAR®, EXPLOTAB®, VIVAPHARM® PVPP), binders (VIVAPHARM® PVP, EMDEX®), lubricants (PRUV®, LUBRITAB®), functional fillers (ARBOCEL®, EMCOMPRESS®, COMPACTROL®), thickeners (VIVAPHARM® Alginates, VIVAPUR® MCG), and specialized disintegrants (EMCOSOY®); (3) VIVACOAT® ready-to-use coating systems including TiO2-free formulations, moisture barriers, enteric coatings, and aesthetic coatings; (4) Technical Services with global Technical Competence Centers providing formulation support and troubleshooting. The portfolio serves pharmaceutical, nutraceutical, animal health, and contract manufacturing industries.

Differentiator

Problem solved

Functional benefit

Products and services

  • VIVAPUR MCC Spheres

Quantifiable outcome

  • 100% satisfactory ratings from top pharmaceutical and nutraceutical companies
  • +1 more outcomes

Companies that use JRS Pharma

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles1 record

JRS Pharma technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

JRS Pharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • CeloniccoreStrategic or Co-development PartnerCelonic is a contract manufacturing organization (CMO) offering development and manufacture of biotherapeutics. They provide development of high yield production cell lines, up-stream and down-stream processes, full GMP analytics, and manufacture of active pharmaceutical ingredients (API) in scales up to 1000L cell cultures. Celonic also performs stability studies of drug substances and products. They joined the JRS Pharma Family to meet growing demands for biotech services.
  • ProJect PharmaceuticscoreStrategic or Co-development PartnerProJect Pharmaceutics transforms proteins, peptides, and ADCs/Cytotoxics into pioneering drugs. With expertise in design, optimization, and customization of pharmaceutical formulations, they deliver and transfer formulations from pilot lab to large-scale manufacturing under GMP environment. Joined the JRS Pharma Family to expand biopharma services.
  • Landerneau Marine Technologies SAScoreTechnology or IntegrationAlginate production facility located on the coast of Brittany, France. Brown algae grow on the continental shelf close to the production site enabling shortest transport routes. Harvesting is regulated by local authorities for optimal sustainability. By-products are re-used or recycled as fertilizer for local agricultural production.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

JRS Pharma competitors and assessment

Company assessment

Broad incumbents

  • BASF: Global chemical giant with a broad pharmaceutical excipients and active ingredient portfolio. Directly comparable to JRS Pharma in binders, disintegrants, and coatings, though BASF spans a far wider industrial chemicals footprint.
  • IFF (DuPont Nutrition & Biosciences): Acquired DuPont's N&B division and offers a large portfolio of pharmaceutical excipients and coatings under the Health & Biosciences segment. Comparable in cellulose-based excipients and broader specialty ingredients.
  • Evonik: German specialty chemicals company with a healthcare-focused excipients portfolio including silica, polyesters, and amino acid derivatives. Comparable in serving global pharma manufacturers with high-purity functional excipients.
  • Shin-Etsu Chemical: Major Japanese specialty chemicals producer offering HPMC, PVP, and other pharmaceutical-grade excipients. Directly competitive with JRS Pharma's VIVAPHARM® HPMC and PVP product lines.

Direct peers

  • Roquette: French-headquartered global leader in pharmaceutical excipients including microcrystalline cellulose, starches, and cyclodextrins. Closest direct competitor to JRS Pharma across both pharma and nutraceutical excipients.
  • DFE Pharma: Netherlands-based dedicated pharmaceutical excipients supplier offering lactose, MCC, superdisintegrants, and inhalation-grade materials. Highly comparable in scale and focus to JRS Pharma's excipient core business.
  • Colorcon: Specialist in film coatings, modified release technologies, and excipients for the pharmaceutical and nutraceutical industries. Direct competitor to JRS Pharma's VIVACOAT® coating line and ready-to-use formulations.
  • Ashland: US-based specialty chemicals company with a pharmaceutical division offering tablet coatings, disintegrants, and binders. Directly comparable in serving pharma and nutraceutical excipient needs.

Emerging players

  • Seppic (Air Liquide Healthcare): Specialty ingredient supplier within Air Liquide offering pharmaceutical and nutraceutical excipients including polymers and coating systems. Comparable in functional coatings and excipient innovation.
  • Kerry Group: Irish taste and nutrition company with a pharmaceutical excipients offering including binders, coatings, and taste-masking technologies. Increasingly comparable to JRS Pharma's nutraceutical-focused portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

JRS Pharma social profiles

Digital presence

JRS Pharma compliance and trust

Trust signal

Compliance6 records

JRS Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

JRS Pharma leadership team

Management profile

Number of profiles

Profiles4 records

JRS Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

JRS Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

JRS Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JRS Pharma

What does JRS Pharma do?

JRS Pharma manufactures and supplies functional excipients and coating systems used by pharmaceutical and nutraceutical companies to formulate solid oral dosage forms such as tablets and capsules. Its portfolio covers binders, fillers, disintegrants, glidants, controlled-release matrix polymers, and ready-to-use film coating systems, complemented by technical services for formulation and coating process support.

Is JRS Pharma a public or private company?

JRS Pharma is a private company. It is classified as family owned and is currently operating.

When was JRS Pharma founded?

JRS Pharma was founded in 1878. It employs 11 to 50 people.

Where is JRS Pharma based?

JRS Pharma is headquartered in Rosenberg, Germany, in the Europe region.

How does JRS Pharma make money?

Four revenue lines are on record. Pharmaceutical Excipients are the primary driver. The others are ready-to-Use Coatings, technical Services and biopharma Services.

Who are JRS Pharma's main competitors?

Broad incumbents on record are BASF, IFF (DuPont Nutrition & Biosciences), Evonik and Shin-Etsu Chemical. Direct peers are Roquette, DFE Pharma, Colorcon and Ashland. Emerging players are Seppic (Air Liquide Healthcare) and Kerry Group.

Does JRS Pharma have an API?

No public API is recorded for JRS Pharma.

What industry is JRS Pharma in?

JRS Pharma's product category is Pharmaceutical Excipients. Its primary akta.pro industry code is HLAIAJAO, Compounding Ingredient & API Distributors (Pharma Supply). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TalkMarketsGlobal Pharmaceutical Grade Dicalcium Phosphate Dihydrate Market Growing at 4.3% CAGR Through 2034According to a new report from Intel Market Research, the global Pharmaceutical Grade Dicalcium Phosphate Dihydrate market was valued at USD 114 million in 2024 and is projected to grow to USD 153 million by 2034, exhibiting a CAGR of 4.3% during the forecast period. The compound is widely used as an excipient in tablet formulations and as a calcium supplement in nutraceuticals, with market growth driven by increasing pharmaceutical demand, rising prevalence of bone-related disorders, and expansion of the global nutraceutical sector. Key market players including ICL, Prayon, JRS PHARMA, and Innophos collectively hold approximately 65% of market share, while emerging manufacturers from China and India are expected to account for 35% of global demand by 2026.openPR.comGlobal Powdered Cellulose Market Outlook: EU Leads Growth as JRS Pharma, Lenzing AG, and Sappi Drive Clean-Label DemandAccording to analysis by Future Market Insights, the EU powdered cellulose market is projected to grow from USD 12.4 million in 2025 to USD 59.3 million by 2036, at a CAGR of 5.0%, driven by rising pharmaceutical manufacturing activity and clean-label food reformulation trends. The food-grade segment accounts for 38% of demand, while direct-to-manufacturer channels dominate distribution at 60%, and the Netherlands leads growth among EU markets at 5.7% CAGR. Key market players including JRS Pharma, Lenzing AG, Sappi Limited, and Roquette Frères compete through product purity, regulatory compliance, and sustainability credentials as the industry shifts toward certified sourcing.Market Research & Business IntelligencePharma Moisture Barrier Film Coating MarketA market research report projects the global pharma moisture barrier film coating market to grow from USD 893.2 million in 2025 to USD 1,309.5 million by 2035, driven by demand for pharmaceutical stability and regulatory compliance. The HPMC polymer type and enteric dissolving solid dosage applications are expected to dominate the market with significant shares. Key players such as Colorcon, JRS Pharma, and Alsiano are identified as leaders in this expanding sector.All4NutraVIVACOAT® free – Experience the future of Titanium Dioxide coating replacement!JRS Pharma has introduced VIVACOAT® free, a titanium dioxide-free tablet coating solution designed to address regulatory bans on TiO2 in food products. The product offers high opacity and brilliant colors with minimal weight gain, targeting challenges faced by nutraceutical companies reformulating their coatings.PR NewswireMicrocrystalline Cellulose Market to be Boosted by High Demand From Food Processing and Pharmaceutical Manufacturing Industries Till 2021 | Million InsightsMillion Insights released a market research report on the global microcrystalline cellulose industry, projecting robust growth through 2021 driven by rising demand from food processing and pharmaceutical manufacturing sectors. The report identifies key industry players including FMC Corporation, Asahi Kasei Corporation, DuPont, JRS Pharma, and Tembec Inc., while noting that North America currently leads the market with Asia Pacific poised as the fastest-growing region due to developing economies and lower regulatory barriers. Key growth factors cited include technological advancements, increased R&D activities, and industrialization across chemical industries globally.PR NewswireMicrocrystalline Cellulose Market 2018 Global Key Manufacturers Analysis and DemandsReportsnReports released a 2018 market research report analyzing the global Microcrystalline Cellulose industry, covering key manufacturers and regional trends. The study details sales, revenue, and market shares for major players including FMC, JRS, and Asahi Kasei across various applications like pharmaceuticals and food.PR NewswireExcipients Market by Oral, Tropical, Parenteral, and Other Routes of Administration for Fillers & Diluents, Disintegrants, Binders & Adhesives, Lubricants & Glidants, Flavors & Sweeteners, Viscosity AThis report analyzes and forecasts the global excipients market at the regional level, covering Latin America with segments including Mexico, Brazil, Argentina, Colombia, Chile, Central America, Caribbean, and Rest of South America. The market is projected from 2015 to 2023 based on volume (tons) and revenue (US$ thousand), examining product segments such as polymers, alcohols, minerals, and gelatin, as well as routes of administration and functional categories. Key players profiled include Ashland Inc., BASF SE, FMC Corporation, The Dow Chemical Company, Merck KGaA, Evonik Industries AG, Croda International Plc, CP Kelco, JRS Pharma, Roquette Pharma, Avantor Performance Materials Inc., Colorcon Inc., Innophos Holdings Inc., Cargill Inc., The Lubrizol Corporation, Eastman Chemical Company, Asahi-Kasei Corporation, Cabot Corporation, and Archer Daniels Midland (ADM) Company.PR NewswireGlobal Microcrystalline Cellulose Market 2015 - Forecasts to 2020 for the $1 Billion IndustryResearch and Markets announced the addition of a market research report on the global microcrystalline cellulose (MCC) market, covering applications in pharmaceutical, food & beverage, cosmetics & personal care, and other sectors. The global MCC market is valued at approximately USD 1,080 million and is expected to grow at a strong CAGR, driven primarily by the pharmaceutical sector and increasing demand from processed food industries in the U.S., Germany, France, China, and India. The report identifies major players including FMC Corporation, Asahi Kasei Corporation, DuPont, DFE Pharma, Tembec Inc., Mingtai Chemical Co. Ltd., JRS Pharma, and Avantor Performance Materials.